Gathering the record
Relay is organizing the evidence and source boundaries.
Unvalidated marketed peptide name
A commercial name used for conflicting proposed compounds and brain-related claims.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
No direct administered-human Adamax study was located.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
The current record is not large enough to characterize uncommon or long-term harms reliably.
No direct evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryNo FDA approval, recognized nonproprietary identity, registered human trial, or peer-reviewed direct evidence located under the name Adamax. The compound’s exact chemical identity, reference standard, pharmacology, and whether any human exposure data exist.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Semax-related naming and proposed modifications do not establish a standardized Adamax product or human dose.
What would fill this gap: Verified sequence, modifications, formulation, and a matching human protocol.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
No single standardized Adamax identity or direct administered-human study was located. Mechanism or Semax background cannot substitute for exact-compound evidence.
Population: No directly studied human population was verified for this identity.
Design: No direct peer-reviewed or registered study located
No direct primary administration source was verified for this exact identity.
Mechanisms
Vendor descriptions disagree about whether Adamax is a modified Semax-related sequence, an adamantane-associated construct, or another formulation. Relay does not infer a mechanism from a disputed name.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Identity-ambiguous; no direct evidence.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The compound’s exact chemical identity, reference standard, pharmacology, and whether any human exposure data exist.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Adamax direct evidence: amounts and schedules describe this route record only.
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Conflicting proposed structures prevent reliable source matching and product comparison. The section remains incomplete because identity, exposure, pharmacology, outcomes, and safety are not established. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Background mechanistic research
Population not stated.
Endpoints were not fully described in the current record.
Semax background does not validate a separately named and structurally disputed Adamax product.
Study administration: Not stated in the current record.
Limitations: No identity or evidence transfer to Adamax.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 16996699